Skip to main content

Table 1 Baseline data for the study cohort

From: Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal

Characteristic

Value

Patients (n = 88)

 

  Male, n (%)

57 (65)

  Female, n (%)

31 (35)

  Mean age ± SD, years

67.8 ± 0.84

Primary tumor

 

  Colon, n (%)

69 (78)

  Rectum, n (%)

19 (22)

Node status

 

  Positive, n (%)

65 (74)

  Negative, n (%)

23 (26)

Colorectal liver metastases (CLM)

 

  Synchronous, n (%)

22 (25)

  Metachronous, n (%)

66 (75)

  Mean number ± SD

2.7 ± 0.13

  Number of 1–3 CLM, n (%)

67 (76)

  Number of 4–5 CLM, n (%)

21 (24)

  Mean maximum size ± SD, cm

3.1 ± 0.1

  Maximum size ≤ 3 cm, n (%)

51 (65)

  Maximum size 3–5 cm, n (%)

27 (35)

CEA levels before RFA, ng/mL

 

  Mean CEA level ± SD

132.2 ± 16.3

  CEA ≤ 100, n (%)

51 (58)

  CEA > 100, n (%)

37 (42)

Main cause of unresectability

 

  Expected liver remnant ≤ 30%, n (%)

19 (22)

  Proximity to critical structures, n (%)

22 (25)

  Medical comorbidity, n (%)

37 (42)

  Patient refusal, n (%)

10 (11)

Systemic therapies before RFA

 

  Mean number of lines ± SD

1.5 ± 0.07

  5-Fluorouracile, n (%)

36 (41)

  5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), n (%)

59 (67)

  5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI), n (%)

41 (47)

  + Bevacizumab, n (%)

13 (15)

  + Cetuximab, n (%)

5 (6)

Systemic therapies before and after RFA

 

  Mean number of lines ± SD

3.1 ± 0.1

  5-Fluorouracile, n (%)

57 (65)

  5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), n (%)

81 (92)

  5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI), n (%)

82 (93)

  + Bevacizumab, n (%)

40 (45)

  + Cetuximab, n (%)

16 (18)

Response to the immediate systemic therapy before RFA

 

  Partial remission, n (%)

49 (56)

  Stable disease, n (%)

13 (15)

  Progressive disease, n (%)

26 (29)

Recurrence after RFA

 

  Median time to recurrence, months (range)

8 (1–24)

  Local tumor progression (RFA-site), n (%)

8 (9)

  Intrahepatic recurrence, n (%)

33 (37)

  Extrahepatic recurrence, n (%)

14 (16)

  Intra-/and extrahepatic recurrence, n (%)

27 (31)

  No recurrence, n (%)

6 (7)

  1. Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; RFA, radiofrequency ablation; SD, standard deviation.